SRx Health Solutions (SRXH) 2024 Sidoti Virtual Micro-Cap Conference summary

Strategic vision and business overview

• Aims to become a global health and wellness company serving both people and pets, anchored by premium pet nutrition and specialty pharmacy operations.

• Halo, the pet food brand, targets high-income, highly engaged pet owners with natural, human-grade products and is experiencing strong growth in Asia-Pacific and the US digital channels.

• SRx Health operates over 30 specialty pharmacy locations in Canada, generating $180 million in revenue with 25% year-over-year growth and plans for continued double-digit expansion.

• SRx's patient support programs provide exclusive access to new therapies for chronic diseases, with new contracts coming online at the end of 2024 and into Q1 2025.

• The combined company leverages SRx’s pharma expertise and distribution to expand into veterinary medicine in FY25.

Market trends and growth drivers

• Pet care market exceeds $130 billion, propelled by trends of pet humanization and premiumization, with consumers seeking high-quality, natural nutrition for pets.

• Specialty pharmacy market is growing due to rising chronic disease prevalence, with 40% of drug use now specialty and expected to increase.

• SRx’s ecosystem includes specialty clinics, clinical trial sites, and proprietary technology, creating high barriers to entry and strong pharma relationships.

• Both businesses benefit from industry tailwinds: aging populations, increased pet ownership, and demand for premium products and specialty care.

• China presents significant growth for pet food, with US brands perceived as premium and the market remaining fragmented and open to challenger brands.

Financial highlights and transaction details

• Combined pro forma net sales for six months reached $95 million with positive EBITDA; Q3 saw 33% revenue growth and 40% gross margin.

• Transaction is an all-stock merger, issuing $20 million in shares to SRx, resulting in $23 million fully diluted shares and a tightly held float.

• TTM sales approach $235 million, with both businesses showing strong organic growth and a promising total addressable market.

• Identified $1.7 million in operational cost synergies and additional revenue synergies from new verticals, especially veterinary health.

• Combined company expects to be cash flow neutral or positive starting in 2025, with SRx generating free cash flow in Q1 2025.